MGF
What the Research Actually Shows
Human: 0 studies, 5 groups · Animal: 1 · In Vitro: 4
The "mechano growth factor" that might not be a growth factor at all — and why the scientific community is still arguing about whether synthetic MGF even works
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
MGF stands for Mechano Growth Factor — a 24-amino-acid piece of a larger protein that one research group says your muscles release after exercise. PEG-MGF is a modified version designed to last longer in the body. Here's the problem: other scientists tested synthetic MGF on muscle cells and found it did nothing at all. Even worse, nobody has ever found the free MGF peptide floating around in human blood or tissue samples. The basic question of whether synthetic MGF has any biological effect is still being argued about in published papers. Zero human trials exist. When peer-reviewed scientists title their paper asking if MGF is "an important cog or a loose screw," the evidence has not reached the point where injecting it makes sense.
Mechano Growth Factor (MGF) is a 24-amino-acid C-terminal peptide fragment of the IGF-1Ec splice variant — one of several alternative forms of IGF-1 mRNA produced when the IGF-1 gene is spliced differently in response to mechanical stress or tissue damage. The hypothesis, developed primarily by Geoffrey Goldspink's laboratory at University College London, proposes that this fragment is released from the pro-IGF-1 protein during post-translational processing and acts as an independent signaling molecule that activates muscle satellite cells.
PEG-MGF is the PEGylated (polyethylene glycol–conjugated) form of this peptide, engineered to extend its half-life from estimated minutes to hours or days by reducing renal clearance and peptidase degradation.
The bodybuilding community adopted MGF and PEG-MGF based on the Goldspink narrative: exercise damages muscle → IGF-1 gene switches to the Ec splice variant → MGF peptide is released → satellite cells activate → muscle repair and growth. The narrative is compelling. The problem is that subsequent research from other laboratories has produced directly contradictory results, including one study showing zero effect of synthetic MGF on primary muscle stem cells (PMID 24253050). The free MGF peptide has never been isolated from any biological sample (PMC 3485521). The fundamental question — does synthetic MGF actually do anything? — remains unresolved.
This article examines the full evidence landscape honestly, including both the positive Goldspink laboratory findings and the critical studies that challenge the entire MGF hypothesis.
In This Article
Quick Facts: MGF at a Glance
Type
Synthetic peptide (24 amino acids) — C-terminal E-peptide of IGF-1Ec splice variant
Also Known As
Mechano Growth Factor, MGF E-peptide, IGF-1Ec E-peptide, PEG-MGF (PEGylated form)
Generic Name
Mechano Growth Factor (no INN assigned)
Brand Name
None — no pharmaceutical product exists
Active Fragment
The synthetic peptide IS the proposed active fragment — whether it functions as claimed is the central scientific dispute
Related Compounds
IGF-1 (parent gene), IGF-1 LR3, IGF-1 DES, GH secretagogues (upstream of IGF-1 splicing)
Molecular Weight
~2,867 Da (MGF); ~5,000+ Da (PEG-MGF, varies by PEG chain length)
Peptide Sequence
24 amino acids from the C-terminal E-domain of the IGF-1Ec splice variant
Endogenous Origin
The IGF-1Ec mRNA splice variant is endogenous and mechano-sensitive. However, free MGF peptide has never been isolated from human biological fluids
Primary Molecular Function
Proposed: satellite cell activation and proliferation via IGF-1Ec E-peptide signaling. Disputed: one key study showed no effect on myoblasts or muscle stem cells
Half-Life
MGF: estimated minutes (rapid peptidase degradation). PEG-MGF: estimated hours to days (PEGylation extends half-life)
Clinical Programs
None. No IND filed. No pharmaceutical development for MGF or PEG-MGF
Route
Intramuscular injection site-specific (community use)
Community Interest
Muscle repair, satellite cell activation, localized muscle growth, recovery from injury. Claims have significantly outpaced evidence
FDA Status
Not approved. Not a pharmaceutical product. Never submitted for regulatory review
WADA Status
Prohibited under S2: Peptide Hormones, Growth Factors. MGF and analogs specifically mentioned
Evidence Tier
4 Preclinical Only
Verdict
Thin Ice
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is MGF / PEG-MGF?
Pronunciation: M-G-F / PEG-M-G-F
Every time you lift something heavy enough to damage muscle fibers, your body activates a repair program. Part of that program involves the IGF-1 gene — but not in the way you might expect. Instead of simply making more IGF-1, your muscle cells splice the IGF-1 gene differently, producing an alternative mRNA transcript called IGF-1Ec (in humans) or IGF-1Eb (in rodents). This splice variant was named "Mechano Growth Factor" by Geoffrey Goldspink's lab at University College London, reflecting its induction by mechanical stress.
The Goldspink hypothesis proposes that when the IGF-1Ec mRNA is translated into protein and then processed, it releases a 24-amino-acid C-terminal fragment — the MGF E-peptide — that functions as an independent signaling molecule. This fragment supposedly activates quiescent satellite cells (muscle stem cells), pushing them into the cell cycle to begin proliferating and ultimately fusing with damaged muscle fibers to drive repair and growth.
The synthetic peptide sold as "MGF" is this 24-amino-acid E-peptide. PEG-MGF is the same peptide with a polyethylene glycol chain attached to extend its half-life from minutes to hours.
Here is where the story gets complicated: no one has ever found the free MGF E-peptide in any biological sample. Not in blood. Not in muscle tissue extracts. Not in cell culture medium from exercised muscle cells. A 2012 critical review in Journal of Applied Physiology — titled "Mechano-Growth Factor: an important cog or a loose screw in the repair machinery?" — explicitly states that the peptide has never been detected as a free entity (PMC 3485521).
PLAIN ENGLISH
The idea behind MGF is that your muscles release a special peptide fragment when they're damaged by exercise, and this fragment tells your muscle stem cells to wake up and start repairing. The problem is that nobody has actually found this peptide floating free in the body. It might exist only as part of a larger protein that never gets cut into fragments. If that's the case, the synthetic version people inject may be a signal that the body never naturally sends.
Origins and Discovery
The MGF story begins in the 1990s at Geoffrey Goldspink's laboratory at University College London. Goldspink's group was studying how mechanical loading affects IGF-1 gene expression in muscle tissue. They discovered that exercise and muscle damage preferentially induced a specific splice variant of the IGF-1 gene — one that included an alternatively spliced E-domain (the Ec exon in humans, Eb in rodents).
Goldspink named this variant "Mechano Growth Factor" in a 2003 publication, proposing that it represented a distinct autocrine/paracrine signal for muscle repair — mechanistically separate from the liver-derived, GH-dependent IGF-1Ea variant that constitutes the bulk of circulating IGF-1 (PMID 20130113).
The hypothesis was elegant: exercise damages muscle → local IGF-1 gene splicing shifts toward the Ec variant → the E-peptide fragment is released → satellite cells activate → muscle repairs and grows. This two-stage model — early MGF for satellite cell activation, followed by later IGF-1Ea for differentiation — provided a compelling framework for understanding exercise-induced muscle hypertrophy.
The synthetic MGF peptide became commercially available through research chemical vendors, and the bodybuilding community adopted it rapidly. PEG-MGF followed as an attempt to solve the obvious pharmacokinetic problem: a 24-amino-acid peptide without PEGylation would be degraded by peptidases within minutes.
The critical question that the Goldspink hypothesis never fully answered — and that subsequent research has challenged — is whether the E-peptide fragment is ever actually released as a free signaling molecule, or whether it exists only as part of the unprocessed pro-IGF-1 protein.
Mechanism of Action
The Goldspink Model (Positive Evidence)
The proposed mechanism follows a stepwise model:
1. Mechanical stress/damage triggers preferential splicing of IGF-1 mRNA toward the Ec variant 2. Translation produces pro-IGF-1Ec protein, which includes the standard IGF-1 peptide plus the unique Ec E-domain 3. Post-translational processing (proposed) cleaves the E-peptide from the mature IGF-1 peptide 4. Free MGF E-peptide activates quiescent satellite cells, driving them into the cell cycle 5. Activated satellite cells proliferate, differentiate, and fuse with damaged fibers
Yang and Goldspink (2002) published evidence that synthetic MGF E-peptide activates human muscle progenitor cells and increases their proliferative potential in culture (PMID 21354439). Qin et al. (2012) showed that MGF promotes proliferation and inhibits differentiation in porcine satellite cells (PMID 22875667).
PLAIN ENGLISH
According to the Goldspink model, MGF is like an alarm bell that goes off in your muscles after exercise. The alarm tells sleeping muscle stem cells to wake up and start multiplying. This is supposed to be the first step in muscle repair — before regular IGF-1 takes over to finish the job.
The Skeptical Counter-Evidence
The MGF hypothesis faces three substantial challenges from independent research:
Challenge 1: The peptide has never been found free. Matheny et al. (2012) conducted a comprehensive critical review and stated explicitly that "no free MGF E-peptide has ever been isolated from cells, conditioned medium, or biological fluids" (PMC 3485521). If the E-peptide is never actually cleaved from the pro-IGF-1 protein, then the synthetic version people inject represents a signal that the body may never naturally produce.
Challenge 2: Direct contradictory evidence. Fornaro et al. (2013) tested synthetic MGF peptide on myoblasts and primary muscle stem cells and reported "no apparent effect" on proliferation, migration, or differentiation (PMID 24253050). This directly contradicts the positive findings from the Goldspink group.
Challenge 3: Single-lab replication problem. The majority of positive results come from Goldspink's laboratory and close collaborators. Independent replication of the satellite cell activation findings has been inconsistent. Internally consistent results from one group, however rigorous, do not constitute the kind of independent replication that establishes a finding as scientifically robust.
PLAIN ENGLISH
Three big problems: (1) nobody has found the peptide floating free in the body, (2) when another lab tested synthetic MGF on muscle cells, nothing happened, and (3) most positive results come from one research group. This doesn't mean MGF is definitely a dud — but it means the evidence is genuinely contested, not just "early."
PEGylation: Solving the Wrong Problem?
PEG-MGF attaches a polyethylene glycol chain to the MGF peptide, extending its half-life from minutes to hours or days. This addresses the pharmacokinetic limitation of rapid peptidase degradation.
But if the fundamental bioactivity of synthetic MGF peptide is disputed — if the compound may not activate satellite cells at all — then extending its half-life solves the wrong problem. A longer-lasting version of a compound that may not work is still a compound that may not work.
Mechanistic Comparison
vs. IGF-1 LR3/DES: These compounds activate a well-characterized receptor (IGF-1R) through a well-characterized mechanism. The pharmacology is not in dispute. MGF's proposed mechanism — independent E-peptide signaling — is itself the subject of scientific debate.
vs. GH secretagogues: GH secretagogues stimulate endogenous IGF-1 production, which includes the natural splicing toward IGF-1Ec in exercised muscle. This is the physiological pathway MGF claims to mimic — but with the natural processing and regulation intact.
vs. BPC-157: Both are proposed repair peptides, but BPC-157 has a larger body of animal evidence showing consistent effects across multiple laboratories. MGF's evidence base is smaller and internally conflicted.
Key Research Areas and Studies
The Positive Case (Goldspink Group)
Goldspink's group published the foundational MGF papers establishing that mechanical loading upregulates IGF-1Ec expression in muscle, that synthetic MGF E-peptide activates human muscle progenitor cells (PMID 21354439), and that MGF promotes satellite cell proliferation while inhibiting premature differentiation (PMID 22875667 — porcine cells).
The model is internally consistent: early MGF signal activates and expands the satellite cell pool, while later IGF-1Ea signaling drives differentiation and fusion. The temporal sequence matches what's observed in muscle repair — satellite cell activation precedes differentiation.
PLAIN ENGLISH
The research group that discovered MGF has shown it works in their lab, using their cells and their methods. The results make biological sense — first wake up the stem cells, then tell them to mature. The question is whether other labs can get the same results.
The Critical Counterpoint
Matheny et al.'s 2012 review (PMC 3485521) is the most comprehensive challenge to the MGF hypothesis. Key points: - Free MGF E-peptide has never been isolated from any biological sample - The processing step that would release the E-peptide from pro-IGF-1Ec has not been demonstrated - The peptide may exist only as part of the unprocessed precursor protein
Fornaro et al. (2013) provided the most damaging experimental evidence: synthetic MGF peptide showed "no apparent effect on myoblasts or primary muscle stem cells" in proliferation, migration, and differentiation assays (PMID 24253050). This study used C2C12 myoblasts and primary human and mouse satellite cells — a broader range of cell types than most positive studies.
PLAIN ENGLISH
When scientists from a different lab tried MGF on muscle cells — including human cells — nothing happened. This isn't a minor quibble about dose or timing. The study found no effect at all on the cells that MGF is supposed to activate. That's a direct contradiction of the founding claim.
Cartilage and Chondrocyte Research
More recent work has explored MGF's potential in cartilage repair, with a 2023 review (PMC 10281885) summarizing evidence for chondrocyte proliferation and cartilage matrix production. This represents a potential pivot in MGF research — away from skeletal muscle and toward connective tissue repair — but the evidence remains preclinical and early.
Growth Hormone Connection
Iida et al. (2004) showed that GH treatment preferentially induces IGF-1Ec (MGF) mRNA expression in GH-deficient mice, suggesting that MGF expression is downstream of GH signaling (PMC 1665252). Shamblott et al. (2008) demonstrated that GH stimulates MGF expression and myoblast transformation in C2C12 cells (PMID 18772608). These studies support the physiological relevance of the IGF-1Ec splice variant but do not address whether the synthetic E-peptide fragment has independent biological activity.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “"MGF activates muscle satellite cells"” | Goldspink group: positive in human progenitor cells (PMID 21354439) and porcine satellite cells (PMID 22875667). Fornaro et al.: no effect on myoblasts or primary muscle stem cells (PMID 24253050). Results are contradictory. | Mixed Evidence |
| “"MGF is released by muscles after exercise"” | The IGF-1Ec mRNA splice variant is upregulated after exercise. But the free E-peptide has never been isolated from any biological sample (PMC 3485521). The processing step is hypothetical. | Mixed Evidence |
| “"PEG-MGF builds muscle"” | Zero human data. The base compound's bioactivity is disputed. PEGylation extends half-life but does not resolve the question of whether synthetic MGF has biological activity. | Preclinical Only |
| “"MGF promotes muscle repair and recovery"” | Plausible based on the Goldspink model but contradicted by the Fornaro negative study. No human data of any kind. | Preclinical Only |
| “"PEG-MGF is better than MGF because it lasts longer"” | PEGylation extends half-life — this is pharmacologically true. But extending the half-life of a compound whose basic activity is disputed solves the wrong problem. | Mixed Evidence |
| “"MGF works through the IGF-1 pathway"” | MGF's proposed mechanism is NOT standard IGF-1R signaling. The E-peptide is proposed to act through an independent, unidentified receptor or signaling mechanism. The IGF-1Ec splice variant includes the standard IGF-1 peptide (which does bind IGF-1R), but the E-peptide fragment alone may not. | Mixed Evidence |
| “"Inject MGF into target muscles for localized growth"” | Community protocol with zero published basis. The localization theory is borrowed from IGF-1 DES protocols but applied to a compound with a disputed mechanism. | Unsupported |
| “"MGF is endogenous so it's safe to inject"” | The IGF-1Ec mRNA is endogenous. The free E-peptide may not exist endogenously. Even if it does, trace endogenous presence does not validate exogenous injection at pharmacological doses. | Unsupported |
| “"200 mcg PEG-MGF per injection is effective"” | Entirely community-derived dosing. No dose-response study exists in any species for synthetic MGF or PEG-MGF. | Unsupported |
| “"MGF helps with cartilage repair"” | Early preclinical evidence for chondrocyte effects (PMC 10281885). Interesting but preliminary — no animal model of cartilage repair has been tested, only cell culture. | Preclinical Only |
| “"MGF is the most anabolic peptide for muscle growth"” | No comparative study exists. The basic bioactivity of synthetic MGF is disputed. Compounds with established IGF-1R signaling (LR3, DES, native IGF-1) have far stronger pharmacological evidence. | Unsupported |
| “"The negative studies just used the wrong dose or form"” | Fornaro et al. (2013) tested synthetic MGF across a range of conditions on multiple cell types. The "wrong conditions" explanation is possible but ad hoc — it's the kind of reasoning that can explain away any negative result indefinitely. | Theoretical |
We currently don’t have any vetted partners for this compound. Check back soon.
The Human Evidence Landscape
There is no human evidence for MGF or PEG-MGF. Zero clinical trials. Zero case reports. Zero observational studies. Zero pharmacokinetic studies. The compound has never been administered to a human in any research context.
More concerning than the absence of human data is the absence of consensus at the preclinical level. For most Tier 4 compounds in Performance and Body Composition, the animal and in vitro evidence is consistent — the mechanism works, the pharmacology is clear, but nobody has tested it in humans. For MGF, the preclinical evidence itself is contradictory. One lab finds satellite cell activation; another finds no effect at all.
What Would Need to Happen for Human Evidence to Emerge
Before any human trial could be justified, the scientific community would need to resolve the fundamental question: does synthetic MGF E-peptide have independent biological activity? This would require: 1. Demonstration that the E-peptide is actually released as a free molecule during natural IGF-1Ec processing 2. Identification of the receptor or signaling mechanism through which the E-peptide acts (currently unknown) 3. Independent replication of the satellite cell activation findings using standardized protocols 4. Resolution of the Fornaro contradiction
Until these questions are answered, a human trial cannot be designed — you cannot dose-find a compound whose target, mechanism, and basic activity are undefined.
PLAIN ENGLISH
Most Tier 4 compounds don't have human data because nobody has gotten around to testing them yet. MGF doesn't have human data because scientists can't even agree on whether it works in a petri dish. That's a more fundamental problem — you can't start human trials for a compound when the basic science is still being debated.
Safety, Risks, and Limitations
Unknown Pharmacokinetics
Neither MGF nor PEG-MGF has been characterized for absorption, distribution, metabolism, or excretion in any species using the synthetic peptide. The half-life estimates (minutes for MGF, hours to days for PEG-MGF) are theoretical, based on general peptide pharmacokinetics and PEGylation properties.
PEG-Related Risks
PEGylated therapeutics carry a small but documented risk of PEG-specific adverse effects: anti-PEG antibody development (which can accelerate clearance and cause hypersensitivity on re-exposure), and rare PEG accumulation in renal tubular cells. These risks are characterized in pharmaceutical-grade PEGylated drugs with known PEG chain lengths and attachment chemistry — none of which is standardized for research chemical PEG-MGF.
Mitogenic Risk
If MGF does activate satellite cells (as the Goldspink data suggests), it functions as a mitogen — a cell proliferation signal. All mitogens carry theoretical oncogenic risk. However, given the disputed bioactivity, this risk may be moot if the compound has no effect.
Product Quality
MGF is a 24-amino-acid peptide — relatively simple to synthesize compared to the larger IGF-1 variants. PEG-MGF is more complex, requiring PEGylation chemistry that varies between vendors. No pharmaceutical standard exists for either product. The PEG chain length, attachment site, and conjugation efficiency may differ between batches and suppliers.
PLAIN ENGLISH
The safety risks of MGF are hard to assess because the basic question of whether it does anything hasn't been answered. If it doesn't work, the main risk is wasting money. If it does work (activating stem cells), then the usual cancer risk from growth signals applies. Either way, you're injecting a research chemical with no quality standards.
The Fundamental Risk: Injecting a Compound That May Not Work
This is the risk that distinguishes MGF from other Performance and Body Composition compounds. IGF-1 LR3 and DES have disputed safety profiles but undisputed pharmacology — they clearly activate IGF-1R. MGF's pharmacology is itself the dispute. The risk of injecting a compound with disputed biological activity is not just a safety question — it's a question of whether you're taking any risk at all in exchange for any benefit at all.
Legal and Regulatory Status
MGF and PEG-MGF are not approved by the FDA for any indication. They have never been submitted for regulatory review and are not pharmaceutical products.
WADA prohibits MGF and its analogs under category S2 (Peptide Hormones, Growth Factors). Myostatin inhibitors including follistatin analogs are prohibited under S4.5.
Both compounds are sold as research chemicals with standard "not for human consumption" disclaimers.
Research Protocols and Formulation Considerations
No published research protocol exists for human administration of MGF or PEG-MGF. All formulation information derives from community experience.
Both compounds are typically supplied as lyophilized powders requiring reconstitution with bacteriostatic water. Storage at 2–8°C (35–46°F). MGF's small size (24 amino acids) makes it relatively straightforward to synthesize but also susceptible to rapid peptidase degradation — the entire rationale for PEGylation.
PEG-MGF reconstitution may differ from standard peptide protocols due to the PEG moiety affecting solubility and stability. No vendor-independent reconstitution guidance exists.
Dosing in Published Research
WHY NO DOSING CHART?
No published dose-response study exists for MGF. The doses reported in the research literature were used in specific experimental contexts, not established through systematic dose-optimization trials. Without controlled data comparing different doses, routes, or durations, we cannot responsibly present a clinical dosing table. What the published studies used is described in the text below.
No published dose-response study exists for MGF or PEG-MGF in any species for muscle growth or repair.
Published studies using synthetic MGF peptide in cell culture (PMID 21354439, PMID 24253050) used micromolar concentrations in vitro — these concentrations cannot be meaningfully extrapolated to injectable doses in vivo due to the entirely different pharmacokinetic environments.
Dosing in Self-Experimentation Communities
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
WHY IS THIS SECTION NEARLY EMPTY?
MGF has limited community usage data. Unlike more widely-used research peptides, there are few reliable community reports on dosing protocols. We include this section for completeness but cannot populate it with data we do not have. As community experience grows, we will update this section accordingly.
The following table summarizes community-reported dosing practices for MGF. These are not clinical recommendations. No controlled trial data supports these protocols.
| Route | Community Use | Evidence | Dose (Range) | Key Risks |
|---|---|---|---|---|
| Intramuscular (MGF) | Site-specific injection into trained muscles | No published evidence; bioactivity disputed | 100–200 mcg per site, bilateral | May have no biological effect; peptidase degradation within minutes |
| Subcutaneous (PEG-MGF) | Systemic injection for extended release | No published evidence | 200–400 mcg, 2–3 times per week | PEG-related immune risk; may have no biological effect |
| Timing (post-workout) | Standard community protocol | No published evidence | Within 30 min of training | Same risks plus hypoglycemia if combined with IGF-1 variants |
Community protocols frequently combine MGF/PEG-MGF with IGF-1 LR3 or DES (MGF for "satellite cell activation," IGF-1 variants for "receptor signaling"). This layering assumes MGF works through a distinct mechanism — an assumption that rests on disputed evidence.
PLAIN ENGLISH
The dosing protocols are entirely from forums and community experience. Given that the basic question of whether MGF works is unresolved, every dose listed above is a guess about how much to take of something that might do nothing.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into MGF combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining MGF with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
| Compound | Type | Evidence Tier | Verdict | Mechanism | Primary Use Case | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|
| IGF-1 LR3 | 83-AA engineered IGF-1 variant (long-acting) | Tier 4 — Preclinical Only | Eyes Open | IGF-1R → PI3K/Akt/mTOR; evades IGFBPs via Arg3→Glu substitution in E-extension; ~2.5× potency of native IGF-1 | Muscle hypertrophy; fat loss; recovery | None — zero human studies | Not approved | Prohibited (S2 — Peptide Hormones, Growth Factors) | Zero human data; same mitogenic pathway that drives cancer; product authenticity variable |
| IGF-1 DES | 67-AA truncated IGF-1 variant (short-acting) | Tier 4 — Preclinical Only | Eyes Open | IGF-1R → PI3K/Akt/mTOR; lacks N-terminal tripeptide → cannot bind IGFBPs; ~10× IGF-1R affinity; rapid clearance (~20–30 min) | Local muscle growth (site injection); fat loss | None — zero human studies | Not approved | Prohibited (S2 — Peptide Hormones, Growth Factors) | Zero human data; extremely short half-life requires precise timing; same cancer-risk axis as LR3 |
| MGF / PEG-MGF | 24-AA E-peptide from IGF-1Ec splice variant (± PEG) | Tier 4 — Preclinical Only | Thin Ice | Proposed: satellite cell activation via E-peptide signaling independent of IGF-1R; PEG extends half-life. Disputed — one key study showed no effect on myoblasts | Muscle repair; satellite cell activation; recovery | None — zero human studies | Not approved | Prohibited (S2 — Peptide Hormones, Growth Factors) | Free MGF E-peptide never isolated from biological fluids; fundamental bioactivity disputed; key negative study (PMID 24253050) |
| Follistatin | 344-AA glycoprotein (~35–40 kDa) | Tier ~ — It's Complicated | Eyes Open | Binds and neutralizes myostatin (GDF-8) + activins → derepression of Smad 2/3 → satellite cell activation → muscle hypertrophy | Muscle growth (myostatin blockade); muscular dystrophy gene therapy | 6 patients in 1 open-label gene therapy trial (Becker MD) | Not approved (IND for gene therapy) | Prohibited (S4.5 — Myostatin Inhibitors) | Human data is gene therapy only — not injectable protein; complex glycoprotein hard to manufacture correctly; broader myostatin inhibitor clinical programs have failed |
Frequently Asked Questions
Does MGF actually work?
This is genuinely unclear. One research group (Goldspink at UCL) has published evidence that synthetic MGF activates muscle progenitor cells. Another group (Fornaro et al.) found no effect on myoblasts or primary muscle stem cells. The free peptide has never been detected in any biological sample. The scientific community has not reached consensus.
What is the difference between MGF and PEG-MGF?
MGF is the raw 24-amino-acid peptide with an estimated half-life of minutes. PEG-MGF has a polyethylene glycol chain attached that extends the half-life to estimated hours or days. PEGylation solves the pharmacokinetic problem (rapid degradation) but does not resolve the fundamental question of whether the base peptide has biological activity.
Is MGF the same as IGF-1?
No. MGF is a proposed fragment of the IGF-1Ec splice variant — specifically the C-terminal E-peptide. It does not bind the IGF-1 receptor and is proposed to work through an entirely different (and currently unidentified) signaling mechanism. The IGF-1 gene produces the standard IGF-1 peptide AND the E-peptide, but they are separate molecules with separate proposed functions.
Has MGF been tested in humans?
No. Zero published human trials for either MGF or PEG-MGF. No IND has been filed. No pharmaceutical development is underway.
Why hasn't anyone found free MGF in the body?
This is the central mystery. The IGF-1Ec mRNA is clearly produced in exercised muscle. But the processing step that would release the E-peptide as a free molecule has never been demonstrated. One possibility: the E-peptide is never cleaved and functions only as part of the intact pro-IGF-1Ec protein. If so, synthetic MGF represents a signal the body never actually sends.
Why did the Fornaro study find no effect?
The Fornaro lab used synthetic MGF peptide on C2C12 myoblasts and primary human and mouse satellite cells across multiple assays — proliferation, migration, differentiation. None showed an effect (PMID 24253050). The Goldspink group's positive results used human muscle progenitor cells with different assay conditions. Whether the discrepancy reflects cell type, assay conditions, peptide quality, or a fundamental non-effect is unresolved.
Is PEG-MGF better than MGF?
PEG-MGF lasts longer in the body. Whether "lasting longer" matters depends entirely on whether the base peptide has biological activity — a question that remains unanswered. Extending the half-life of an inactive compound provides no benefit.
Can I combine MGF with IGF-1 LR3 or DES?
Community protocols layer MGF (for "satellite cell activation") with IGF-1 variants (for "receptor signaling"). This assumes MGF works through a distinct mechanism — an assumption based on disputed evidence. Combining unproven compounds does not make either one more proven.
What does "mechano-sensitive" mean for MGF?
The IGF-1Ec splice variant is upregulated by mechanical loading (exercise, muscle damage). This is well-established at the mRNA level. The leap from "mRNA is mechano-sensitive" to "the free peptide fragment is released and signals independently" is the part that remains unproven.
Is MGF safe to inject?
The safety profile cannot be meaningfully assessed because the basic pharmacology is unknown. If MGF has no biological effect, the primary risk is injection-related (infection, PEG immune reactions with PEG-MGF). If MGF does activate satellite cells, standard mitogenic risks apply. No human safety data exists.
Why is MGF rated Thin Ice when other Tier 4 compounds are Eyes Open?
Other Tier 4 compounds in Performance and Body Composition (IGF-1 LR3, IGF-1 DES) have undisputed pharmacology — they clearly activate a known receptor through a known mechanism. The evidence gap is in human testing, not in basic science. For MGF, the basic science itself is disputed. When peer-reviewed scientists publish papers questioning whether the compound works at all, the evidence base is weaker than "no human data" — it's "no consensus on whether it works in any species."
Could MGF be useful for cartilage repair?
A 2023 review (PMC 10281885) summarized early evidence for MGF effects on chondrocytes and cartilage matrix production. This is an interesting alternative application, but the evidence is preliminary (cell culture only) and faces the same fundamental questions about synthetic E-peptide bioactivity.
Summary of Key Findings
MGF / PEG-MGF represents the most speculative compound in Performance and Body Composition — and one of the most speculative on Peptidings. The evidence base is not merely thin. It is actively disputed.
The positive case: Goldspink's laboratory produced a coherent model of exercise-induced IGF-1 splicing, E-peptide release, and satellite cell activation. The temporal logic (early activation signal distinct from later differentiation signal) fits the biology of muscle repair. Results in human progenitor cells and porcine satellite cells show measurable effects.
The critical problems: (1) Free MGF E-peptide has never been isolated from any biological sample, raising the question of whether the synthetic product represents a real endogenous signal. (2) An independent laboratory found zero effect of synthetic MGF on myoblasts and primary muscle stem cells. (3) The receptor or signaling mechanism for the E-peptide has never been identified. (4) Positive results are concentrated in one research group without robust independent replication.
PEG-MGF adds PEGylation engineering to solve a half-life problem for a compound whose basic bioactivity is disputed — a pharmacokinetic solution to what may be a pharmacological non-problem.
Community use of MGF/PEG-MGF has far outpaced not just the human evidence (zero) but even the scientific consensus about whether the compound works. When the evidence community has not agreed on basic bioactivity, community adoption represents a level of optimism that the data does not support.
PLAIN ENGLISH
MGF is the one compound in this cluster where the problem isn't "no human data" — it's "scientists can't agree on whether it works at all." The founding research group says it activates muscle stem cells. Another lab says it does nothing. The actual peptide has never been found free in the body. If you inject MGF, you're not just the clinical trial — you're betting on one side of an unresolved scientific argument.
Verdict Recapitulation
This is the weakest evidence base in Performance and Body Composition and one of the weakest on the site. MGF earns Thin Ice — not Eyes Open — because the evidence dispute is not about human translation (the normal Tier 4 gap) but about fundamental biological activity. The question is not "does this work in humans?" but "does this work at all?" That uncertainty, combined with zero human data and product quality concerns, warrants the lowest confidence rating.
For readers considering MGF, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source MGF
Further Reading and Resources
If you want to go deeper on MGF, the evidence landscape for performance & body composition peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Performance & Body Composition Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: MGF — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Yang SY, Goldspink G. (2002). "Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation." FEBS Lett, 522(1-3), 156–160. PMID 21354439
- Matheny RW, Nindl BC, Adamo ML. (2012). "Mechano-growth factor: an important cog or a loose screw in the repair machinery?" J Appl Physiol, 112(7), 1257–1258. PMC: 3485521
- Fornaro M, Hinken AC, Bhatt S, et al. (2013). "Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells." Am J Physiol Endocrinol Metab, 306(2), E150–E156. PMID 24253050
- Qin LL, Li XK, Xu J, et al. (2012). "Mechano growth factor (MGF) promotes proliferation and inhibits differentiation of porcine satellite cells by down-regulating Mef2 family expression." Reprod Domest Anim, 47(3), 449–454. PMID 22875667
- Goldspink G. (2010). "Research on mechano growth factor: its potential for optimising physical training as well as misuse in doping." Br J Sports Med, 39(11), 787–788. PMID 20130113
- Ma Y, Liu X, Liu Y, et al. (2023). "Mechano-growth factor in cartilage repair: a review of research progress." Front Cell Dev Biol, 11, 1209386. PMC: 10281885
- Shamblott MJ, Leung S, Martin GM. (2008). "Growth hormone stimulates MGF expression and C2C12 myoblast transformation." Growth Horm IGF Res, 18(1), 21–23. PMID 18772608
- Iida K, Itoh E, Kim DS, et al. (2004). "Growth hormone increases mRNA of mechano-growth factor in GH-deficient mice." J Endocrinol, 181(3), 423–427. PMC: 1665252
DISCLAIMER
MGF is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 11, 2026. Next scheduled review: October 08, 2026.
About the Author
Lawrence Winnerman
Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.